Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab

Traditional Chinese Medicine and Ranibizumab in the Treatment of Macular Cystoid Edema Associated With Retinal Vein Obstruction.

The objective of this study was to investigate the efficacy and safety of traditional Chinese medicine (Jueling Mingmu Decoction) combined with ranibizumab in the treatment of macular edema with retinal vein obstructive.

Compared to the sole intravitreal injection of ranibizumab, the combined use of traditional Chinese medicine with intravitreal ranibizumab aims to determine if it is more effective in alleviating macular cystoid edema secondary to retinal branch vein occlusion, leading to improved visual prognosis and potentially reducing the frequency of intravitreal drug injections.

Inclusion Criteria:

• Foveal center-involved macular edema (ME) lasting less than 9 months
• Central Macular Thickness (CMT) greater than or equal to 250 μm
• Best-Corrected Visual Acuity (BCVA) of 24-73 letters (20/40 to 20/320) in the study eye
• Initial diagnosis with no prior treatments, such as laser therapy or intravitreal injections

Exclusion Criteria:

• Presence of any additional macular pathology, such as age-related macular degeneration (AMD) or diabetic retinopathy (DR) affecting the macula
• Concurrent serious conditions, such as cardiovascular diseases, liver, or kidney diseases
• Concerns or doubts regarding treatment
• Known allergies to the ingredients of the medication.